Patents Assigned to Basilea Pharmaceutica AG
  • Patent number: 10222377
    Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: March 5, 2019
    Assignees: BASILEA PHARMACEUTICA AG, RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG
    Inventors: Heidi Alexandra Lane, Felix Bachmann, Madlaina Breuleux, Michael Boutros, Daniel Gilbert, Xian Zhang
  • Patent number: 10221206
    Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: March 5, 2019
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 10067120
    Abstract: Use of acetylated tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazoles compound of general formula (I).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 4, 2018
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 10006078
    Abstract: Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that for Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I).
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 26, 2018
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 9995754
    Abstract: Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 12, 2018
    Assignee: Basilea Pharmaceutica AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 9970938
    Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula I wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a group C?Y, wherein Y stands for ox
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 15, 2018
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann, Madlaina Breuleux, Michael Boutros, Daniel Gilbert, Xian Zhang
  • Patent number: 9783508
    Abstract: The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: October 10, 2017
    Assignee: Basilea Pharmaceutica AG
    Inventors: Ruben Van Summeren, Harrie Vaessen, Daniel Mink, Mario Waser
  • Patent number: 9738676
    Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof and their use as PDE4 inhibitors.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 22, 2017
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 9511064
    Abstract: The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: December 6, 2016
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Jens Pohlmann, Don Gary Benjamin, Christoph Moroni
  • Patent number: 9476889
    Abstract: Use of acetylated tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazoles compound of general formula (I).
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: October 25, 2016
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 9366682
    Abstract: Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 14, 2016
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 9321788
    Abstract: The present invention relates to antibacterial compounds of formula I: wherein all variable substituents are defined as described herein, which are useful for the treatment of bacterial infections.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: April 26, 2016
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Berangere Gaucher, Franck Hubert Danel, Tong Xie, Lin Xu
  • Patent number: 9163034
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: October 20, 2015
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Marco Alpegiani, Jr., Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Patent number: 9133219
    Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 15, 2015
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
  • Patent number: 9120822
    Abstract: The present invention relates to antibacterial compounds of formula I: wherein all variable substituents are defined as described herein, which are useful for the treatment of bacterial infections.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: September 1, 2015
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Berangere Gaucher, Jr., Franck Hubert Danel, XiaoHu Tang, Tong Xie, Lin Xu
  • Patent number: 8933073
    Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: January 13, 2015
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 8927541
    Abstract: The present invention relates to antibacterial compounds of formula I: wherein all variable substituents are defined as described herein, which are useful for the treatment of bacterial infections.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 6, 2015
    Assignee: Basilea Pharmaceutica AG
    Inventors: Bérangère Gaucher, Franck Hubert Danel, XiaoHu Tang, Tong Xie, Lin Xu
  • Patent number: 8927542
    Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 6, 2015
    Assignee: Basilea Pharmaceutica AG
    Inventors: Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
  • Publication number: 20150005491
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: Basilea Pharmaceutica AG
    Inventors: Marco Alpegiani, JR., Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Patent number: 8901293
    Abstract: New monobactam antibiotics compounds which contain an 3-amino-azetidin-2-one ring and are active against gram-negative bacteria, wherein the compounds include the compound 2-(2-amino-thiazol-4-yl)-2-[(Z)-(1H,4H-1,5-dihydroxy-4-oxo-pyridin-2-yl)methoxyimino]-N-[3(S)-1-oxysulfonyl-2,2-dimethyl-4-oxo-azetidin-3-yl]acetamide.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: December 2, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Eric Desarbre, Bérangére Gaucher, Malcolm G. P. Page, Patrick Roussel